0000899243-20-018510.txt : 20200706
0000899243-20-018510.hdr.sgml : 20200706
20200706191125
ACCESSION NUMBER: 0000899243-20-018510
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200701
FILED AS OF DATE: 20200706
DATE AS OF CHANGE: 20200706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gerard Christopher
CENTRAL INDEX KEY: 0001694097
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24260
FILM NUMBER: 201014788
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY, SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMEDISYS INC
CENTRAL INDEX KEY: 0000896262
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082]
IRS NUMBER: 113131700
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
BUSINESS PHONE: 2252922031
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
FORMER COMPANY:
FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP
DATE OF NAME CHANGE: 19940819
FORMER COMPANY:
FORMER CONFORMED NAME: M&N CAPITAL CORP
DATE OF NAME CHANGE: 19930125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-01
0
0000896262
AMEDISYS INC
AMED
0001694097
Gerard Christopher
3854 AMERICAN WAY, SUITE A
BATON ROUGE
LA
70816
0
1
0
0
Chief Operating Officer
Common Stock
2020-07-01
4
S
0
97
199.34
D
33573
D
Common Stock
2020-07-01
4
S
0
121
200.31
D
33452
D
Common Stock
2020-07-01
4
S
0
99
201.57
D
33353
D
Common Stock
2020-07-01
4
S
0
44
202.80
D
33309
D
Common Stock
2020-07-01
4
S
0
25
204.10
D
33284
D
Common Stock
2020-07-01
4
S
0
106
205.17
D
33178
D
Common Stock
2020-07-01
4
S
0
189
206.25
D
32989
D
Common Stock
2020-07-01
4
S
0
66
207.01
D
32923
D
Common Stock
2020-07-01
4
S
0
3
208.05
D
32920
D
Common Stock
279
I
Through 401(k) Plan
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.97 to $199.91, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.98 to $200.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.24 to $202.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.35 to $203.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.65 to $204.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.72 to $205.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.72 to $206.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.77 to $207.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.00 to $208.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (10) to this Form 4.
The information in this report is based on a plan statement dated as of March 31, 2020.
/s/ Jennifer R. Guckert, pursuant to a power of attorney
2020-07-06